Straight answers to common arthritis questions

Sources

1. A BMJ network meta-analysis of 10 large trials in 3,803 patients found that compared with placebo the difference in pain intensity on a 10 cm visual analogue scale was -0.4 cm for glucosamine, -0.3 cm for chondroitin and -0.5 cm for the combination - none crossing the pre-specified minimal clinically important difference of -0.9 cm. Industry-independent trials showed smaller effects than commercially funded ones (P=0.02 for interaction).

   Wandel S, et al. — Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis.. BMJ, 2010. DOI: 10.1136/bmj.c4675.

2. In a 70-participant randomized double-blind placebo-controlled trial, Curcuma longa extract improved VAS knee pain versus placebo by -9.1 mm (95% CI -17.8 to -0.4, P=0.039) and WOMAC pain by -47.2 mm, but did NOT change effusion-synovitis volume on MRI or cartilage composition. The authors flag modest sample size and 12-week duration as limitations.

   Wang Z, et al. — Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis : A Randomized Trial.. Ann Intern Med, 2020. DOI: 10.7326/M20-0990.

3. A two-year randomized placebo-controlled trial in 146 participants with symptomatic knee OA raised serum 25-hydroxyvitamin D by a mean 16.1 ng/mL with cholecalciferol 2000 IU/day, testing whether vitamin D supplementation reduces symptom and structural progression of knee osteoarthritis.

   McAlindon T, et al. — Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial.. JAMA, 2013. DOI: 10.1001/jama.2012.164487.

4. A web-based case-crossover study of 345 people with symptomatic radiographic knee OA (171 with at least one flare, 1,425 observations) found NO apparent association between temperature, relative humidity, air pressure or precipitation and the risk of knee pain exacerbation - directly contradicting the near-universal patient belief that weather drives flares.

   Ferreira ML, et al. — The influence of weather on the risk of pain exacerbation in patients with knee osteoarthritis - a case-crossover study.. Osteoarthritis Cartilage, 2016. DOI: 10.1016/j.joca.2016.07.016.

5. In 1,212 Osteoarthritis Initiative participants aged 50+ with knee OA, those who walked for exercise had a LOWER likelihood of developing new frequent knee pain than non-walkers (odds ratio 0.6, 95% CI 0.4-0.8), and less progression of medial joint space narrowing - evidence against the belief that walking wears the joint out faster.

   Lo GH, et al. — Association Between Walking for Exercise and Symptomatic and Structural Progression in Individuals With Knee Osteoarthritis: Data From the Osteoarthritis Initiative Cohort.. Arthritis Rheumatol, 2022. DOI: 10.1002/art.42241.

6. A meta-analysis of nine randomized trials (898 participants) found dietary interventions improved osteoarthritis pain (SMD -0.67, 95% CI -1.01 to -0.34) and physical function (SMD -0.62). The benefit was concentrated in REDUCED-ENERGY diets (pain SMD -0.85); the Mediterranean diet subgroup did NOT significantly change pain (SMD -0.27, 95% CI -1.14 to 0.60, P=0.54).

   Asadi S, et al. — The effectiveness of dietary intervention in osteoarthritis management: a systematic review and meta-analysis of randomized clinical trials.. Eur J Clin Nutr, 2025. DOI: 10.1038/s41430-025-01622-0.

7. FDA states verbatim that stem cell products, stromal vascular fraction (adipose-derived), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products have NOT been approved 'for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.